Sonis S T
Division of Oral Medicine, Oral and Maxillofacial Surgery and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Oral Oncol. 1998 Jan;34(1):39-43. doi: 10.1016/s1368-8375(97)00053-5.
Mucositis induced by antineoplastic drugs is an important, dose-limiting and costly side effect of cancer therapy. The ulcerative lesions which result are frequent systemic portals of entry for microorganisms which inhabit the mouth and consequently are often sources of systemic infection in the myelosuppressed patient. A number of clinical observations and the inconsistency of responses to a broad range of treatment modalities suggests a physiological complexity to mucositis which has not previously been comprehensively considered. We now propose a hypothesis as to the mechanism by which mucositis develops and resolves, which is based on four phases: an initial inflammatory/vascular phase; an epithelial phase; an ulcerative/bacteriological phase; and a healing phase. The role of cytokines as initiators and ampliers of the process is discussed, as is the potential influence of genetic factors in establishing risk and modifying the course of stomatotoxicity.
抗肿瘤药物引起的黏膜炎是癌症治疗中一种重要的、剂量限制性且代价高昂的副作用。由此产生的溃疡性病变常常是口腔微生物进入全身的通道,因此在骨髓抑制患者中往往是全身感染的源头。一系列临床观察以及对多种治疗方式反应的不一致表明,黏膜炎存在一种此前未被全面考虑的生理复杂性。我们现在提出一个关于黏膜炎发生和消退机制的假说,该假说基于四个阶段:初始炎症/血管阶段;上皮阶段;溃疡/细菌学阶段;以及愈合阶段。文中讨论了细胞因子作为该过程启动者和放大器的作用,以及遗传因素在确定风险和改变口腔毒性病程方面的潜在影响。